Trials / Withdrawn
WithdrawnNCT01106053
Pramipexole for Binge Eating Disorder
An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate the effects that the drug pramipexole has on mood, food craving, and other behaviors that may be related to binge eating disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramipexole | Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day). |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-07-01
- First posted
- 2010-04-19
- Last updated
- 2013-05-06
Source: ClinicalTrials.gov record NCT01106053. Inclusion in this directory is not an endorsement.